id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-6564-0002,FDA,FDA-2017-D-6564,"Best Practices for Communication Between IND Sponsors and FDA
During Drug Development Guidance for Industry and Review Staff",Other,Guidance,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2024-11-07T01:15:37Z,,1,0,0900006482d7eb23
FDA-2017-D-6564-0001,FDA,FDA-2017-D-6564,"Best Practices for Communication Between Investigational New Drug
Application Sponsors and the Food and Drug Administration; Guidance for Industry and Review Staff; Availability",Notice,Notice of Availability,2017-12-29T05:00:00Z,2017,12,2017-12-29T05:00:00Z,,2017-12-29T14:28:34Z,2017-28139,0,0,0900006482d832c0